122
Participants
Start Date
October 31, 2005
Primary Completion Date
January 31, 2008
Study Completion Date
January 31, 2008
Epoetin beta
Participants will receive epoetin beta as a weekly subcutaneous (SC) injection over an 8-week correction phase with 60 international units per kilograms (IU/kg) as starting dose. Baseline weight will be used to determine the dose and adjustments in the dose will be implemented based on the participant's blood hemoglobin levels. Participants with a response to correction treatment will then enter a 4-week extension phase to receive the SC injection every 2 weeks, and those without response will continue at the same weekly dose for a 4-week continuation phase.
Blois
Aix-en-Provence
Marseille
Martigues
Saintes
Brivé
Dijon
Saint-Brieuc
Besançon
Valence
Évreux
Chartres
Quimper
Valence
Nîmes
Toulouse
Muret
Bordeaux
Bordeaux
Bordeaux
Montpellier
Béziers
Bourgoin
La Tronche
Mont-de-Marsan
Orléans
Angers
Saint-Lô
Reims
Vandœuvre-lès-Nancy
Thionville
Nevers
Lille
Valenciennes
Maubeuge
Beauvais
Creil
Arras
Bois-Bernard
Boulogne
Clermont-Ferrand
Chamalières
Cabestany
Haguenau
Colmar
Greize
Pierre-Bénite
Le Mans
Évian-les-Bains
Paris
Paris
Paris
Le Havre
Rouen
Bois-Guillaume
Harfleur
Melun
Tournan-en-Brie
Trappes
Poissy
Niort
Salouël
Figanières
La Roche-sur-Yon
Poitiers
Limoges
Sens
Évry
Montreuil
Aubervilliers
Créteil
Le Kremlin-Bicêtre
Thiais
Saint-Maurice
Annonay
Bourg-en-Bresse
Gap
Saint-Laurent-du-Var
Hoffmann-La Roche
INDUSTRY